R U Ostrovskaya Selected Research

ethyl phenylacetyl-Pro-Gly

12/2019	Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled Prediabetes.
1/2016	Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept.
1/2013	Efficiency of noopept in streptozotocin-induced diabetes in rats.
9/2008	Noopept stimulates the expression of NGF and BDNF in rat hippocampus.
7/2008	Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats).
7/2008	Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade.
4/2007	Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R U Ostrovskaya Research Topics

Disease

6	Type 2 Diabetes Mellitus (MODY) 05/2022 - 04/2017
6	Hyperglycemia 12/2019 - 04/2017
5	Alzheimer Disease (Alzheimer's Disease) 07/2013 - 03/2005
4	Weight Loss (Weight Reduction) 10/2020 - 01/2013
3	Polydipsia 01/2019 - 09/2018
3	Hyperphagia (Overeating) 01/2019 - 09/2018
3	Body Weight (Weight, Body) 09/2018 - 01/2013
2	Diabetes Mellitus 05/2022 - 04/2018
2	Hypoxia (Hypoxemia) 01/2016 - 10/2000
2	Cognitive Dysfunction 09/2008 - 04/2007
2	Schizophrenia (Dementia Praecox) 03/2005 - 11/2003
1	Diabetic Neuropathies (Diabetic Neuropathy) 05/2022
1	Prediabetic State (Prediabetes) 12/2019
1	Dementia (Dementias) 04/2017
1	Pain (Aches) 01/2013
1	Memory Disorders (Memory Loss) 07/2008
1	Learning Disabilities (Learning Disability) 03/2005
1	Brain Ischemia (Cerebral Ischemia) 09/2000

Drug/Important Bio-Agent (IBA)

10	Streptozocin (Streptozotocin)FDA Link 05/2022 - 01/2013
7	ethyl phenylacetyl-Pro-GlyIBA 12/2019 - 04/2007
5	DipeptidesIBA 12/2019 - 09/2000
4	Hypoglycemic Agents (Hypoglycemics)IBA 05/2022 - 04/2018
3	Nerve Growth Factor (NGF)IBA 05/2022 - 07/2013
2	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 10/2000
2	2- ((2- morpholino)ethylthio)- 5- ethoxybenzimidazoleIBA 10/2020 - 09/2018
2	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 01/2016
2	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 09/2018
2	Nootropic Agents (Nootropics)IBA 01/2013 - 07/2008
2	Cholinergic Agents (Cholinergics)IBA 07/2008 - 04/2007
2	Scopolamine (Hyoscine)FDA Link 04/2007 - 03/2005
2	Pharmaceutical PreparationsIBA 04/2007 - 03/2005
2	GZR 123IBA 03/2005 - 11/2003
1	Lysine (L-Lysine)FDA Link 05/2022
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 10/2020
1	Malondialdehyde (Propanedial)IBA 12/2019
1	LithiumIBA 10/2018
1	SaltsIBA 10/2018
1	Lithium Carbonate (Eskalith)FDA LinkGeneric 10/2018
1	Lithium ChlorideIBA 10/2018
1	Anti-Anxiety Agents (Anxiolytics)IBA 09/2018
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2018
1	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2016
1	Neuroprotective AgentsIBA 01/2013
1	Nerve Growth Factors (Neurotrophins)IBA 09/2008
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 07/2008
1	Cholinergic ReceptorsIBA 04/2007
1	Choline (Choline Chloride)IBA 03/2005
1	levodopa drug combination benserazideIBA 03/2005
1	ArgonIBA 10/2000

Therapy/Procedure

1	Therapeutics 05/2022
1	Aftercare (After-Treatment) 09/2018
1	Injections 03/2005
1	Oral Administration 09/2000